The emerging role of miRNAs in inflammatory bowel disease: A review

Therapeutic Advances in Gastroenterology

Volumn 8, Issue 1, 2015, Pages 4-22

  Chapman, Christopher G ^a   Pekow, Joel ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

epigenetics; inflammatory bowel disease; microRNA

Indexed keywords

ANTAGOMIR; MICRORNA; MICRORNA 106A; MICRORNA 126; MICRORNA 155; MICRORNA 192; MICRORNA 200B; MICRORNA 21; MICRORNA 29; NANOPARTICLE; SMALL UNTRANSLATED RNA; UNCLASSIFIED DRUG; VIRUS VECTOR;

BLOOD ANALYSIS; CROHN DISEASE; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE EXPRESSION; GENETIC RISK; HERITABILITY; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINAL FIBROSIS; PATHOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ULCERATIVE COLITIS;

EID: 84919493836     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X14547360     Document Type: Review

References (122)

1. Almanza G. Anufreichik V. Rodvold J. Chiu K. Delaney A. Akers J. et al. (2013) Synthesis and delivery of short, noncoding RNA by B lymphocytes. Proc Natl Acad Sci U S A 110: 20182–20187.
2. Babar I. Cheng C. Booth C. Liang X. Weidhaas J. Saltzman W. et al. (2012) Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A 109: E1695–E1704.
3. Bae H. Noh J. Kim J. Eun J. Jung K. Kim M. et al. (2014) MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT 1 in hepatocellular carcinoma. Oncogene 33: 2557–2567.
4. Bartel D. (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215–233.
5. Behlke M. (2008) Chemical modification of siRNAs for in vivo use. Oligonucleotides 18: 305–319.
6. Beitzinger M. Meister G. (2010) Preview. MicroRNAs: from decay to decoy. Cell 140: 612–614.
7. Bian Z. Li L. Cui J. Zhang H. Liu Y. Zhang C. et al. (2011) Role of MIR-150-targeting C-MYB in colonic epithelial disruption during dextran sulphate sodium-induced murine experimental colitis and human ulcerative colitis. J Pathol 225: 544–553.
8. Biancheri P. (2013) Micro-RNA expression profiling identifies miR-29b as a relevant pro-fibrogenic factor in Crohn's disease intestinal strictures. In: Proceedings of the 8th Congress of the European Crohn's and Colitis Organisation, Poster presentations: Basic science: P 057:
9. Brain O. Owens B. Pichulik T. Allan P. Khatamzas E. Leslie A. et al. (2013) The intracellular sensor NOD 2 induces microRNA-29 expression in human dendritic cells to limit IL-23 release. Immunity 39: 521–536.
10. Brest P. Lapaquette P. Souidi M. Lebrigand K. Cesaro A. Vouret-Craviari V. et al. (2011) A Synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. Nat Genet 43: 242–245.
11. Bushati N. Cohen S. (2007) Microrna functions. Annu Rev Cell Dev Biol 23: 175–205.
12. Chen X. Ba Y. Ma L. Cai X. Yin Y. Wang K. et al. (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997–1006.
13. Chen Y. Wang C. Liu Y. Tang L. Zheng M. Xu C. et al. (2013 a) miR-122 targets NOD 2 to decrease intestinal epithelial cell injury in Crohn's disease. Biochem Biophys Res Commun 438: 133–139.
14. Chen Y. Xiao Y. Ge W. Zhou K. Wen J. Yan W. et al. (2013 b) miR-200b inhibits TGF-beta1-induced epithelial-mesenchymal transition and promotes growth of intestinal epithelial cells. Cell Death Dis 4: e541.
15. Choi W. Giraldez A. Schier A. (2007) Target protectors reveal dampening and balancing of nodal agonist and antagonist by miR-430. Science 318: 271–274.
16. Chuang A. Chuang J. Zhai Z. Wu F. Kwon J. (2014) NOD2 expression is regulated by microRNAs in colonic epithelial HCT 116 cells. Inflamm Bowel Dis 20: 126–135.
17. Coskun M. Bjerrum J. Seidelin J. Troelsen J. Olsen J. Nielsen O. (2013) miR-20b, miR-98, miR-125b-1*, and let-7e* as new potential diagnostic biomarkers in ulcerative colitis. World J Gastroenterol 19: 4289–4299.
18. Crawford M. Brawner E. Batte K. Yu L. Hunter M. Otterson G. et al. (2008) MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun 373: 607–612.
19. Czauderna F. Fechtner M. Dames S. Aygun H. Klippel A. Pronk G. et al. (2003) Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 31: 2705–2716.
20. Dombkowski A. Sultana Z. Craig D. Jamil H. (2011) In silico analysis of combinatorial microRNA activity reveals target genes and pathways associated with breast cancer metastasis. Cancer Inform 10: 13–29.
21. Duttagupta R. Dirienzo S. Jiang R. Bowers J. Gollub J. Kao J. et al. (2012) Genome-wide maps of circulating miRNA biomarkers for ulcerative colitis. PloS ONE 7: e31241.
22. Eiring A. Harb J. Neviani P. Garton C. Oaks J. Spizzo R. et al. (2010) miR-328 functions as an RNA decoy to modulate hnRNP e 2 regulation of mrna translation in leukemic blasts. Cell 140: 652–665.
23. Evel-Kabler K. Song X. Aldrich M. Huang X. Chen S. (2006) SOCS1 restricts dendritic cells’ ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest 116: 90–100.
24. Fasseu M. Treton X. Guichard C. Pedruzzi E. Cazals-Hatem D. Richard C. et al. (2010) Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PloS ONE 5: e13160.
25. Feng R. Chen X. Yu Y. Su L. Yu B. Li J. et al. (2010) miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett 298: 50–63.
26. Feng X. Wang H. Ye S. Guan J. Tan W. Cheng S. et al. (2012) Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IkappaBalpha. PloS ONE 7: e52782.
27. Friedman R. Farh K. Burge C. Bartel D. (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92–105.
28. Garzon R. Marcucci G. Croce C. (2010) Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9: 775–789.
29. Georges S. Biery M. Kim S. Schelter J. Guo J. Chang A. et al. (2008) Coordinated regulation of cell cycle transcripts by P53-inducible microRNAs, miR-192 and miR-215. Cancer Res 68: 10105–10112.
30. Hampe J. Franke A. Rosenstiel P. Till A. Teuber M. Huse K. et al. (2007) A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn's disease in ATG16l1. Nat Genet 39: 207–211.
31. Henry J. Park J. Jiang J. Kim J. Nagorney D. Roberts L. et al. (2010) miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 403: 120–125.
32. Homer C. Richmond A. Rebert N. Achkar J. McDonald C. (2010) ATG16l1 and NOD 2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn's disease pathogenesis. Gastroenterology 139: 1630–1641, 1641 e 1631–1632.
33. Hon L. Zhang Z. (2007) The roles of binding site arrangement and combinatorial targeting in microRNA repression of gene expression. Genome Biol 8: R166.
34. Hsu S. Wang B. Kota J. Yu J. Costinean S. Kutay H. et al. (2012) Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 122: 2871–2883.
35. Huang Z. Shi T. Zhou Q. Shi S. Zhao R. Shi H. et al. (2014) miR-141 regulates colonic leukocytic trafficking by targeting CXCL12β during murine colitis and human Crohn's disease. Gut 63: 1247–1257.
36. Iborra M. Bernuzzi F. Correale C. Vetrano S. Fiorino G. Beltran B. et al. (2013) Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease. Clin Exp Immunol 173: 250–258.
37. Ivanovska I. Ball A. Diaz R. Magnus J. Kibukawa M. Schelter J. et al. (2008) microRNAs in the miR-106b family regulate P21/CDKN1a and promote cell cycle progression. Mol Cell Biol 28: 2167–2174.
38. Janssen H. Reesink H. Lawitz E. Zeuzem S. Rodriguez-Torres M. Patel K. et al. (2013) Treatment of HCV infection by targeting microRNA. N Engl J Med 368: 1685–1694.
39. Kato M. Zhang J. Wang M. Lanting L. Yuan H. Rossi J. et al. (2007) microRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A 104: 3432–3437.
40. Kent O. McCall M. Cornish T. Halushka M. (2014) Lessons from miR-143 / 145: the importance of cell-type localization of miRNAs. Nucleic Acids Res 42: 7528–7538.
41. Khor B. Gardet A. Xavier R. (2011) Genetics and pathogenesis of inflammatory bowel disease. Nature 474: 307–317.
42. Kota J. Chivukula R. O'Donnell K. Wentzel E. Montgomery C. Hwang H. et al. (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005–1017.
43. Koukos G. Polytarchou C. Kaplan J. Morley-Fletcher A. Gras-Miralles B. Kokkotou E. et al. (2013) microRNA-124 regulates STAT 3 expression and is downregulated in colon tissues of pediatric patients with ulcerative colitis. Gastroenterology 145: 842–852 e842.
44. Krek A. Grun D. Poy M. Wolf R. Rosenberg L. Epstein E. et al. (2005) Combinatorial microRNA target predictions. Nat Genet 37: 495–500.
45. Krol J. Busskamp V. Markiewicz I. Stadler M. Ribi S. Richter J. et al. (2010) Characterizing light-regulated retinal microRNAs reveals rapid turnover as a common property of neuronal microRNAs. Cell 141: 618–631.
46. Krutzfeldt J. Kuwajima S. Braich R. Rajeev K. Pena J. Tuschl T. et al. (2007) Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res 35: 2885–2892.
47. Krutzfeldt J. Rajewsky N. Braich R. Rajeev K. Tuschl T. Manoharan M. et al. (2005) Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438: 685–689.
48. Lagos-Quintana M. Rauhut R. Lendeckel W. Tuschl T. (2001) Identification of novel genes coding for small expressed RNAs. Science 294: 853–858.
49. Lapaquette P. Glasser A. Huett A. Xavier R. Darfeuille-Michaud A. (2010) Crohn's disease-associated adherent-invasive E. coli are selectively favoured by impaired autophagy to replicate intracellularly. Cell Microbiol 12: 99–113.
50. Lapierre J. Salomon W. Cardia J. Bulock K. Lam J. Stanney W. et al. (2011) Potent and systematic RNAi mediated silencing with single oligonucleotide compounds. RNA 17: 1032–1037.
51. Lee R. Feinbaum R. Ambros V. (1993) The C. elegans heterochronic gene LIN-4 encodes small RNAs with antisense complementarity to LIN-14. Cell 75: 843–854.
52. Lennox K. Behlke M. (2011) Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther 18: 1111–1120.
53. Leung A. Sharp P. (2010) MicroRNA functions in stress responses. Mol Cell 40: 205–215.
54. Li Q. Chau J. Ebert P. Sylvester G. Min H. Liu G. et al. (2007) miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 129: 147–161.
55. Li Z. Lu J. Sun M. Mi S. Zhang H. Luo R. et al. (2008) Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A 105: 15535–15540.
56. Lin J. Welker N. Zhao Z. Li Y. Zhang J. Reuss S. et al. (2014) Novel specific microRNA biomarkers in idiopathic inflammatory bowel disease unrelated to disease activity. Mod Pathol 27: 602–608.
57. Lindsay J. Ciesielski C. Scheinin T. Brennan F. Hodgson H. (2003) Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut 52: 363–369.
58. Lindsay J. van Montfrans C. Brennan F. van Deventer S. Drillenburg P. Hodgson H. et al. (2002) IL-10 gene therapy prevents TNBs-induced colitis. Gene Ther 9: 1715–1721.
59. Liu G. Friggeri A. Yang Y. Milosevic J. Ding Q. Thannickal V. et al. (2010) miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 207: 1589–1597.
60. Liu Y. Cui H. Wang W. Li L. Wang Z. Yang S. et al. (2013) Construction of circular miRNA sponges targeting miR-21 or miR-221 and demonstration of their excellent anticancer effects on malignant melanoma cells. Int J Biochem Cell Biol 45: 2643–2650.
61. Lu C. Chen J. Xu H. Zhou X. He Q. Li Y. et al. (2014) miR106b and miR 93 prevent removal of bacteria from epithelial cells by disrupting ATG16l1-mediated autophagy. Gastroenterology 146: 188–199.
62. Lu Y. Xiao J. Lin H. Bai Y. Luo X. Wang Z. et al. (2009) A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microrna interference. Nucleic Acids Res 37: e24.
63. Majid S. Dar A. Saini S. Yamamura S. Hirata H. Tanaka Y. et al. (2010) microRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer 116: 5637–5649.
64. Marlow G. van Gent Ferguson L. (2013) Why interleukin-10 supplementation does not work in Crohn's disease patients. World J Gastroenterol 19: 3931–3941.
65. Masotti A. (2012) Interplays between gut microbiota and gene expression regulation by miRNAs. Front Cell Infect Microbiol 2: 137.
66. Maurer B. Stanczyk J. Jungel A. Akhmetshina A. Trenkmann M. Brock M. et al. (2010) microRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum 62: 1733–1743.
67. McCarroll S. Huett A. Kuballa P. Chilewski S. Landry A. Goyette P. et al. (2008) Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat Genet 40: 1107–1112.
68. Mendell J. Olson E. (2012) microRNAs in stress signaling and human disease. Cell 148: 1172–1187.
69. Mingozzi F. Maus M. Hui D. Sabatino D. Murphy S. Rasko J. et al. (2007) Cd8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 13: 419–422.
70. Mitchell P. Parkin R. Kroh E. Fritz B. Wyman S. Pogosova-Agadjanyan E. et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105: 10513–10518.
71. Molodecky N. Kaplan G. (2010) Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol 6: 339–346.
72. Mori S. Takeuchi T. Enomoto Y. Kondo K. Sato K. Ono F. et al. (2008) Tissue distribution of cynomolgus adeno-associated viruses AAV10, AAV11, and AAVCY.7 in naturally infected monkeys. Arch Virol 153: 375–380.
73. Murakami Y. Toyoda H. Tanaka M. Kuroda M. Harada Y. Matsuda F. et al. (2011) The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PloS ONE 6: e16081.
74. Murugaiyan G. Beynon V. Mittal A. Joller N. Weiner H. (2011) Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. J Immunol 187: 2213–2221.
75. Nathwani A. Tuddenham E. Rangarajan S. Rosales C. McIntosh J. Linch D. et al. (2011) Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365: 2357–2365.
76. Nguyen H. Dalmasso G. Muller S. Carriere J. Seibold F. Darfeuille-Michaud A. (2014) Crohn's disease-associated adherent invasive Escherichia coli modulate levels of microRNAs in intestinal epithelial cells to reduce autophagy. Gastroenterology 146: 508–519.
77. Nguyen H. Dalmasso G. Yan Y. Laroui H. Dahan S. Mayer L. et al. (2010) microRNA-7 modulates CD98 expression during intestinal epithelial cell differentiation. J Biol Chem 285: 1479–1489.
78. Oba S. Kumano S. Suzuki E. Nishimatsu H. Takahashi M. Takamori H. et al. (2010) miR-200b precursor can ameliorate renal tubulointerstitial fibrosis. PloS ONE 5: e13614.
79. Ogura Y. Bonen D. Inohara N. Nicolae D. Chen F. Ramos R. et al. (2001) A Frameshift mutation in NOD 2 associated with susceptibility to Crohn's disease. Nature 411: 603–606.
80. Paraskevi A. Theodoropoulos G. Papaconstantinou I. Mantzaris G. Nikiteas N. Gazouli M. (2012) Circulating microRNA in inflammatory bowel disease. J Crohns Colitis 6: 900–904.
81. Parkes M. Barrett J. Prescott N. Tremelling M. Anderson C. Fisher S. et al. (2007) Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 39: 830–832.
82. Pasquinelli A. Reinhart B. Slack F. Martindale M. Kuroda M. Maller B. et al. (2000) Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 408: 86–89.
83. Pecot C. Calin G. Coleman R. Lopez-Berestein G. Sood A. (2011) RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 11: 59–67.
84. Peer D. Park E. Morishita Y. Carman C. Shimaoka M. (2008) Systemic Leukocyte-directed siRNA delivery revealing cyclin D 1 as an anti-inflammatory target. Science 319: 627–630.
85. Pekow J. Dougherty U. Mustafi R. Zhu H. Kocherginsky M. Rubin D. et al. (2012) miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inflamm Bowel Dis 18: 94–100.
86. Plank M. Maltby S. Mattes J. Foster P. (2013) Targeting translational control as a novel way to treat inflammatory disease: the emerging role of microRNAs. Clin Exp Allergy 43: 981–999.
87. Polyak S. Mach A. Porvasnik S. Dixon L. Conlon T. Erger K. et al. (2012) Identification of adeno-associated viral vectors suitable for intestinal gene delivery and modulation of experimental colitis. Am J Physiol Gastrointest Liver Physiol 302: G296–G308.
88. Prideaux L. de Cruz P. Ng S. Kamm M. (2012) Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 18: 1340–1355.
89. Pritchard C. Kroh E. Wood B. Arroyo J. Dougherty K. Miyaji M. et al. (2012) Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res 5: 492–497.
90. Roderburg C. Urban G. Bettermann K. Vucur M. Zimmermann H. Schmidt S. et al. (2011) Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 53: 209–218.
91. Sandborn W. Gasink C. Gao L. Blank M. Johanns J. Guzzo C. et al. (2012) Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 367: 1519–1528.
92. Sharma A. Kumar M. Aich J. Hariharan M. Brahmachari S. Agrawal A. et al. (2009) Posttranscriptional regulation of interleukin-10 expression by hsa-miR-106a. Proc Natl Acad Sci U S A 106: 5761–5766.
93. Shi C. Liang Y. Yang J. Xia Y. Chen H. Han H. et al. (2013) microRNA-21 knockout improve the survival rate in DSS induced fatal colitis through protecting against inflammation and tissue injury. PloS ONE 8: e66814.
94. Sibley C. Seow Y. Wood M. (2010) Novel RNA-based strategies for therapeutic gene silencing. Mol Ther 18: 466–476.
95. Singh S. Davis A. Taylor G. Deretic V. (2006) Human IRGM Induces autophagy to eliminate intracellular mycobacteria. Science 313: 1438–1441.
96. Sonkoly E. Janson P. Majuri M. Savinko T. Fyhrquist N. Eidsmo L. et al. (2010) miR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4. J Allergy Clin Immunol 126: 581–589 e581–520.
97. Soriano A. Jubierre L. Almazan-Moga A. Molist C. Roma J. de Toledo J. et al. (2013) microRNAs as pharmacological targets in cancer. Pharmacol Res 75: 3–14.
98. Spehlmann M. Begun A. Burghardt J. Lepage P. Raedler A. Schreiber S. (2008) Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study. Inflamm Bowel Dis 14: 968–976.
99. Stanczyk J. Pedrioli D. Brentano F. Sanchez-Pernaute O. Kolling C. Gay R. et al. (2008) Altered expression of microRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 58: 1001–1009.
100. Stein E. Dufour R. Gagne C. Gaudet D. East C. Donovan J. et al. (2012) Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 126: 2283–2292.
101. Takagi T. Naito Y. Mizushima K. Hirata I. Yagi N. Tomatsuri N. et al. (2010) Increased expression of microRNA in the inflamed colonic mucosa of patients with active ulcerative colitis. J Gastroenterol Hepatol 25 Suppl 1: S129–S133.
102. Thum T. Gross C. Fiedler J. Fischer T. Kissler S. Bussen M. et al. (2008) microRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456: 980–984.
103. Tremaine W. (2011) Diagnosis and treatment of indeterminate colitis. Gastroenterol Hepatol 7: 826–828.
104. Tsai W. Hsu S. Hsu C. Lai T. Chen S. Shen R. et al. (2012) microRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 122: 2884–2897.
105. Vasudevan S. Tong Y. Steitz J. (2007) Switching from repression to activation: microRNAs can up-regulate translation. Science 318: 1931–1934.
106. Vettori S. Gay S. Distler O. (2012) Role of microRNAs in fibrosis. Open Rheumatol J 6: 130–139.
107. Wightman B. Ha I. Ruvkun G. (1993) Posttranscriptional regulation of the heterochronic gene LIN-14 by LIN-4 mediates temporal pattern formation in C. elegans. Cell 75: 855–862.
108. Wolfrum C. Shi S. Jayaprakash K. Jayaraman M. Wang G. Pandey R. et al. (2007) Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 25: 1149–1157.
109. Worm J. Stenvang J. Petri A. Frederiksen K. Obad S. Elmen J. et al. (2009) Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of C / EBP beta and down-regulation of G-CSF. Nucleic Acids Res 37: 5784–5792.
110. Wu F. Guo N. Tian H. Marohn M. Gearhart S. Bayless T. et al. (2011) Peripheral blood microRNAs distinguish active ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 17: 241–250.
111. Wu F. Zhang S. Dassopoulos T. Harris M. Bayless T. Meltzer S. et al. (2010) Identification of microRNAs associated with ileal and colonic Crohn's disease. Inflamm Bowel Dis 16: 1729–1738.
112. Wu F. Zikusoka M. Trindade A. Dassopoulos T. Harris M. Bayless T. et al. (2008) microRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology 135: 1624–1635 e1624.
113. Wu H. Neilson J. Kumar P. Manocha M. Shankar P. Sharp P. et al. (2007) miRNA profiling of naive, effector and memory CD8 T cells. PloS ONE 2: e1020.
114. Xiang S. Fruehauf J. Li C. (2006) Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. Nat Biotechnol 24: 697–702.
115. Yang Y. Ma Y. Shi C. Chen H. Zhang H. Chen N. et al. (2013) Overexpression of miR-21 in patients with ulcerative colitis impairs intestinal epithelial barrier function through targeting the Rho GTPase Rho B. Biochem Biophys Res Commun 434: 746–752.
116. Zahm A. Thayu M. Hand N. Horner A. Leonard M. Friedman J. (2011) Circulating microRNA is a biomarker of pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 53: 26–33.
117. Zarjou A. Yang S. Abraham E. Agarwal A. Liu G. (2011) Identification of a microRNA signature in renal fibrosis: role of miR-21. Am J Physiol Renal Physiol 301: F793–F801.
118. Zhai Z. Wu F. Chuang A. Kwon J. (2013) miR-106b fine tunes ATG16l1 expression and autophagic activity in intestinal epithelial HCT 116 cells. Inflamm Bowel Dis 19: 2295–2301.
119. Zhai Z. Wu F. Dong F. Chuang A. Messer J. Boone D. et al. (2014) Human autophagy gene ATG16L1 is post-transcriptionally regulated by MIR142-3p. Autophagy 10: 468–479.
120. Zhang H. (2009) Reversal of HIV-1 latency with anti-microRNA inhibitors. Int J Biochem Cell Biol 41: 451–454.
121. Zhang Y. Cristofaro P. Silbermann R. Pusch O. Boden D. Konkin T. et al. (2006) Engineering mucosal RNA interference in vivo. Mol Ther 14: 336–342.
122. Zhang Y. Wang Z. Gemeinhart R. (2013) Progress in microRNA delivery. J Control Release 172: 962–974.